TherapeuticsMD Inc  

(Public, NYSEMKT:TXMD)   Watch this stock  
Find more results for TXMD
4.55
+0.03 (0.66%)
Jul 22 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 4.47 - 4.70
52 week 2.03 - 9.01
Open 4.54
Vol / Avg. 1.50M/2.72M
Mkt cap 661.75M
P/E     -
Div/yield     -
EPS -0.22
Shares 145.44M
Beta 4.94
Inst. own 66%
Jun 24, 2014
TherapeuticsMD Inc at JMP Securities Healthcare Conference
Jun 16, 2014
TherapeuticsMD Inc Investor Day
Jun 5, 2014
TherapeuticsMD Inc Annual Shareholder Meeting
Jun 3, 2014
TherapeuticsMD Inc at Jefferies Global Healthcare Conference
May 13, 2014
TherapeuticsMD Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2014
TherapeuticsMD Inc at Mizuho Securities USA Healthcare Corporate Access Day
May 5, 2014
Q1 2014 TherapeuticsMD Inc Earnings Conference Call
May 5, 2014
Q1 2014 TherapeuticsMD Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -324.43% -323.84%
Operating margin -316.22% -294.09%
EBITD margin - -293.43%
Return on average assets -63.73% -83.66%
Return on average equity -72.61% -106.71%
Employees 69 -
CDP Score - -

Address

3rd Floor, 6800 Broken Sound Parkway NW
BOCA RATON, FL 33487
United States - Map
+1-561-9611900 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TherapeuticsMD Inc., is a specialty pharmaceutical company. The Company is focused on creating branded prescription, generic prescription and over-the-counter (non-prescription) products targeted for women. The Company�s products include vitalmedMD Plus Rx, vitalmedMD One Rx, vitalmedMD Redichew Rx, vitalmedMD Plus, vitalmedMD One, vitalmedMD Menopause Relief, vitalmedMD Iron 21/7, vitalmedMD D3 2000IU, vitalmedMD D3 50000IU, vitalmedMD Women�s Multivitamin, VMD Signature Collection Stretch Mark Cream, Prena 1, Prena 1 Plus and Prena 1 Chew. The Company�s pipeline includes TX 12-001HR , TX 12-002HR, TX 12-003HR and TX 12-004HR. The Company�s TX 12-001HR is a combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal dryness, for post-menopausal women with an intact uterus.

Officers and directors

Tommy G. Thompson J.D. Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
John C. K. Milligan IV President, Secretary, Director
Age: 51
Bio & Compensation  - Reuters
Robert G. Finizio Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Daniel A. Cartwright Chief Financial Officer, Vice President - Finance, Treasurer
Age: 56
Bio & Compensation  - Reuters
Mitchell L. Krassan Executive Vice President, Chief Strategy Officer
Age: 48
Bio & Compensation  - Reuters
Joel S. Krasnow M.D., Chief Scientific Officer, Head - Regulatory Department
Bio & Compensation  - Reuters
Brian Bernick M.D. Chief Clinical Officer, Director
Age: 45
Bio & Compensation  - Reuters
Sebastian Mirkin M.D. Chief Medical Officer
Bio & Compensation  - Reuters
Cooper C. Collins Independent Director
Age: 35
Bio & Compensation  - Reuters
Robert V. LaPenta Independent Director
Age: 45
Bio & Compensation  - Reuters